UY27486A1 - Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas - Google Patents

Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Info

Publication number
UY27486A1
UY27486A1 UY27486A UY27486A UY27486A1 UY 27486 A1 UY27486 A1 UY 27486A1 UY 27486 A UY27486 A UY 27486A UY 27486 A UY27486 A UY 27486A UY 27486 A1 UY27486 A1 UY 27486A1
Authority
UY
Uruguay
Prior art keywords
queratinocits
active substance
biologically active
wound treatment
treatment
Prior art date
Application number
UY27486A
Other languages
English (en)
Inventor
P Eberhardt
W Noe
K Reif
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27486A1 publication Critical patent/UY27486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a queratinocitos cultivables in vitro, así como a su uso ventajoso para la preparación de un producto, que se puede utilizar para el tratamiento de heridas agudas y crónicas.
UY27486A 2001-10-17 2002-10-14 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas UY27486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (de) 2001-10-17 2001-10-17 Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden

Publications (1)

Publication Number Publication Date
UY27486A1 true UY27486A1 (es) 2003-05-30

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27486A UY27486A1 (es) 2001-10-17 2002-10-14 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Country Status (30)

Country Link
US (3) US7247478B2 (es)
EP (1) EP1440148B1 (es)
JP (1) JP4476625B2 (es)
KR (1) KR101019916B1 (es)
CN (1) CN100432220C (es)
AR (1) AR036827A1 (es)
AT (1) ATE474039T1 (es)
AU (1) AU2002349352B2 (es)
BR (1) BR0213282A (es)
CA (1) CA2461141C (es)
CO (1) CO5580844A2 (es)
DE (2) DE10151296A1 (es)
DK (1) DK1440148T3 (es)
EA (1) EA009073B1 (es)
EC (1) ECSP045065A (es)
ES (1) ES2345767T3 (es)
HR (1) HRP20040347B1 (es)
HU (1) HU228887B1 (es)
IL (2) IL161442A0 (es)
MX (1) MXPA04003487A (es)
MY (1) MY137828A (es)
NO (1) NO334974B1 (es)
NZ (1) NZ532899A (es)
PE (1) PE20030627A1 (es)
PL (1) PL367338A1 (es)
RS (1) RS30104A (es)
UA (1) UA81398C2 (es)
UY (1) UY27486A1 (es)
WO (1) WO2003033686A2 (es)
ZA (1) ZA200402306B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP3100611B1 (en) 2003-08-01 2018-09-12 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2006010161A2 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5478497B2 (ja) * 2007-10-19 2014-04-23 バイオイントラフェイス，インク． 新規組成物、ならびに関連する方法、コーティング、および物品
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
WO2011154402A1 (en) * 2010-06-09 2011-12-15 Chanel Parfums Beaute Inhibitors of micro-rnas for use for preventing and/or attenuating skin ageing and/or for hydrating skin
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2015518843A (ja) * 2012-05-25 2015-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 創傷、例えば、糖尿病性創傷の処置における、ｄｐｐ−４阻害剤と組み合わせてもよい生物活性物質としてのケラチン生成細胞の使用
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN105219697A (zh) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 一种人原代角质细胞分离制备的方法
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
JP2019518428A (ja) * 2016-04-12 2019-07-04 ユニシテ エーファウ アクチェンゲゼルシャフト 体液試料からの細胞外小胞（ｅｖ）の単離
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
CN109055303A (zh) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 一种皮肤组织的构建方法
RU2731065C1 (ru) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Состав криоконсерванта для длительного хранения первичных кератиноцитов

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (it) 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (it) 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
JP3311351B2 (ja) * 1991-11-20 2002-08-05 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 新規なケラチノサイト培養物，その調製方法及び創傷治療物質としてのその用途
US6585969B1 (en) 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
US5891617A (en) 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (de) 1999-04-19 2000-10-26 Christian Toloczyki Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten

Also Published As

Publication number Publication date
UA81398C2 (en) 2008-01-10
MY137828A (en) 2009-03-31
AU2002349352B2 (en) 2007-11-01
IL161442A0 (en) 2004-09-27
KR101019916B1 (ko) 2011-03-08
US7247478B2 (en) 2007-07-24
CO5580844A2 (es) 2005-11-30
NZ532899A (en) 2006-04-28
WO2003033686A3 (de) 2004-02-12
US20030091542A1 (en) 2003-05-15
EP1440148B1 (de) 2010-07-14
HUP0600341A2 (en) 2006-08-28
ES2345767T3 (es) 2010-10-01
DE10151296A1 (de) 2003-04-30
DK1440148T3 (da) 2010-09-27
CN1571835A (zh) 2005-01-26
DE50214540D1 (de) 2010-08-26
CN100432220C (zh) 2008-11-12
RS30104A (en) 2006-10-27
WO2003033686A2 (de) 2003-04-24
US20070065419A1 (en) 2007-03-22
US7306943B2 (en) 2007-12-11
EA009073B1 (ru) 2007-10-26
EA200400482A1 (ru) 2004-12-30
ECSP045065A (es) 2004-05-28
KR20040045856A (ko) 2004-06-02
US7754481B2 (en) 2010-07-13
NO334974B1 (no) 2014-08-11
CA2461141A1 (en) 2003-04-24
MXPA04003487A (es) 2004-07-30
ZA200402306B (en) 2006-05-31
JP4476625B2 (ja) 2010-06-09
BR0213282A (pt) 2004-10-26
ATE474039T1 (de) 2010-07-15
HUP0600341A3 (en) 2011-03-28
HRP20040347B1 (en) 2012-07-31
CA2461141C (en) 2011-12-06
NO20041570L (no) 2004-04-16
JP2005505392A (ja) 2005-02-24
US20080131967A1 (en) 2008-06-05
IL161442A (en) 2012-02-29
PE20030627A1 (es) 2003-07-16
AR036827A1 (es) 2004-10-06
HRP20040347A2 (en) 2005-04-30
EP1440148A2 (de) 2004-07-28
PL367338A1 (en) 2005-02-21
HU228887B1 (hu) 2013-06-28

Similar Documents

Publication Publication Date Title
UY27486A1 (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
UY27720A1 (es) Aroilpiridinonas monocíclicas,
ITPD20050207A1 (it) Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
MX2008000243A (es) Material de curacion para heridas.
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
MY149601A (en) Masking the taste of powders
MX352315B (es) Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
ATE339224T1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
UY28313A1 (es) Nonadepsipeptidos acilados
ECSP056186A (es) Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas
UY28622A1 (es) Agentes antibacterianos de quinolona
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
CL2004000625A1 (es) Composicion farmaceutica que comprende tolterodina y cacao en polvo; su uso en la fabricacion de medicamento util para el tratamiento de vejiga hiperactiva.
BRPI0506557A (pt) uso do metronidazol para a preparação de uma composição farmacêutica
CL2004001607A1 (es) Uso de gabaxafol para preparar un medicamento util en el tratamiento de la depresion.
ECSP044966A (es) Compuesto polimorfo estable de flibanserina, procedimeinto industrial para su preparacion, y uso del mismo para preparar medicamentos
BRPI0419032A (pt) composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do cáncer
ECSP003367A (es) Procedimiento para preparar secretagogos de hormonas del crecimiento
HN2000000059A (es) Derivado sustituido de pirazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150928